Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem ...
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip
Even with this partial rebound, Lilly's share price remains roughly 13% below the peak set in late August. Some investors ...
Eli Lilly Just Hit a Milestone That Disappointed. Here's Why You Should Still Buy the Stock.
Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...
Indianapolis Recorder13h
Eli Lilly CEO named Life Sciences Champion of the Year
BioCrossroads has named Eli Lilly CEO, Dave Ricks, the recipient of the 2024 August M. Watanabe Life Sciences Champion of the ...
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still fell short
Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
Futurism on MSN10d
Eli Lilly Has a Major Problem With Its Weight Loss Drugs Zepbound and Mounjaro
Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed what Bloomberg called a "shocking first miss" in its ...
The Associated Press - Business News on MSN13d
Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop
Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...
Eli Lilly set to snap six straight sessions of losses
Eli Lilly (NYSE:LLY) shares were on track to snap six straight sessions of losses on Thursday, as the stock rose 1.9% at $790 ...
Eli Lilly grows Milwaukee-area footprint with $40.8M warehouse acquisition — and more
Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...
Is Eli Lilly Stock a Buy?
However, Eli Lily is a fast-growing company, with a price/earnings-to-growth ratio (PEG ratio) of only 0.5. PEGs under 1 are ...
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...